ArgusEye technology proven by TESTA-center in Uppsala, Sweden

A groundbreaking system for biological drug production and control

ArgusEye develops a leading system for inline quality measurement of biological drug development and production. We have been collaborating since 2018 conducting NY Consulting services for international value chain validated market potential project, Go-to-Market strategy development and fundraising. It is therefore an internationally commercially validated company close to reach a substantial market with a unique product.

This was validated as the company was selected to participate in the TESTA Center challenge week - an initiative developed by Cytiva (formerly GE Healthcare). The objective is to identify and support new production technologies that can improve production and outcome of biological drugs.

The ArgusEye sensor system exceeded expectations and proved assumptions

The ArgusEye sensor system surpassed expectations as this short quote illustrate:

(…) we began further analysis using the ÄKTA pure 25. But this time it was modified to integrate ArgusEye’s in-line nanoplasmonic sensor into the flow path enabling an additional high-tech detection method. Erik’s years of experience paid off – the result was better than expected according to the UNICORN software analysis as well as data from ArgusEye’s system.

An ongoing fundraising process with committed anchor investor

The current fundraising process is open to investors that wish to join a syndicate with a leading venture capital fund as committed anchor investor.

Contact Johan Ny for more information on johan.ny@nyconsulting.se or log on to www.arguseye.se.

ArgusEye CEO Erik Martinsson working with and testing the ArgusEye inline sensor technology with the ÄKTA System by Cytiva (Former GE Healthcare)